3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
40
Recurrence
9
Neoplasms, Plasma Cell
7
Waldenstrom Macroglobulinemia
3
Neoplasms
3
Lymphoma, B-Cell
3
Burkitt Lymphoma
3
Sarcoma, Kaposi
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Acquired Immunodeficiency Syndrome
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Renal Insufficiency
1
Plasmablastic Lymphoma
1
Optic Nerve Glioma
1
Neurofibromatosis 1
1
Myeloproliferative Disorders
1
Multi-centric Castleman's Disease
1
Leukemia, Myeloid, Acute
1
Intraocular Lymphoma
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Epstein-Barr Virus Infections
1
Disease Progression
1
Disease
1
Central Nervous System Neoplasms
1
Amyloidosis
1
Interventions
Paclitaxel
2
Kidney Transplantation
2
Cyclophosphamide
2
Azacitidine
2
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pomalidomide
1
pevonedistat
1
osimertinib
1
mirabegron
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
dabrafenib
1
copanlisib
1
belinostat
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Topotecan
1
Taxes
1
Sitagliptin Phosphate
1
Rituximab
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Methotrexate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Renal Insufficiency
×
pomalidomide
×
Clear all
NCT01575925
2022-11-04
POM Renal
Celgene
Phase 1
Completed
25 enrolled